Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 4Colorectal Neoplasms 3Neoplasms 2Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Digestive System Neoplasms 1Desmoid Tumors 1Adrenocortical Carcinoma 1

Interventions

lutetium Lu 177 dotatate 3Octreotide 3pasireotide 2lanreotide 2amino-acid, glucose, and electrolyte solution 2Everolimus 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2famitinib 1copper dotatate CU-64 1arginyllysine 1Temozolomide 1Sunitinib 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1PM 01183 1Oxaliplatin 1Lutetium-177 1Lutetium 1Leucovorin 1Irinotecan 1Folfox protocol 1Fluorouracil 1E-7386 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gastro-enteropancreatic neuroendocrine tumor × E-7386 × Clear all
NCT03833700 2026-02-27

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Eisai Inc.

Phase 1 Active not recruiting
70 enrolled
EndocrineGastrointestinalNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Desmoid Tumors, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡